When should an apolipoprotein B (apoB) test be ordered?

When to Order Apolipoprotein B (ApoB) Testing

Order apoB testing when triglycerides are ≥1.5 mmol/L (≥133 mg/dL) or ≥200 mg/dL, as LDL-C becomes unreliable at these levels and apoB provides a more accurate assessment of atherogenic particle burden. 1, 2

Primary Indications for ApoB Measurement

Hypertriglyceridemia (Most Common Indication)

• Measure apoB when fasting triglycerides ≥200 mg/dL because the Friedewald equation for calculating LDL-C becomes increasingly inaccurate above this threshold and is invalid when triglycerides exceed 400 mg/dL 3, 2
• Consider apoB when triglycerides are ≥1.5 mmol/L (≥133 mg/dL), as cholesterol in LDL particles is replaced by triglyceride at this level, promoting small dense LDL particles and making LDL-C an unreliable reflection of particle number 1
• ApoB directly measures the concentration of all atherogenic particles (VLDL, IDL, LDL, remnants, and Lp(a)), providing superior risk assessment compared to LDL-C in this setting 1

Diabetes and Metabolic Conditions

• Order apoB in patients with diabetes mellitus or insulin resistance syndrome, even when LDL-C appears at target, to assess residual cardiovascular risk 4, 3
• ApoB is particularly valuable in type 2 diabetes patients with ≥2 additional ASCVD risk factors, as it more accurately reflects the atherogenic burden from remnant lipoproteins and small dense LDL 4
• In diabetic patients, use apoB to guide treatment intensity: target <90 mg/dL for high-risk, <80 mg/dL for very high-risk, and <70 mg/dL for extreme-risk patients 4

Risk Assessment in Primary Prevention

• Measure apoB in adults aged 40-75 years undergoing primary prevention risk assessment when overall cardiovascular risk is uncertain, as it serves as a risk-enhancing factor 2, 5
• ApoB ≥130 mg/dL corresponds to LDL-C ≥160 mg/dL and should prompt initiation or intensification of statin therapy as a risk-enhancing factor 4, 2, 6
• Consider apoB testing in intermediate-risk individuals (10-year ASCVD risk 7.5-20%) to refine risk stratification and guide treatment decisions 3, 6

Very Low LDL-C Levels

• Order apoB when LDL-C is <70 mg/dL (<1.8 mmol/L), especially if triglycerides exceed 150 mg/dL, because the Friedewald equation is unreliable at such low LDL-C concentrations 2
• This scenario is increasingly common in patients on intensive statin therapy or combination lipid-lowering regimens 2

Family History and Genetic Disorders

• Measure apoB in adults with family history of premature ASCVD (men <55 years, women <65 years) to aid identification of familial lipid disorders and guide cascade screening 2, 6
• ApoB testing helps diagnose distinct lipoprotein phenotypes when used in tandem with standard lipid measurements, improving identification of inherited lipoprotein syndromes 7

Established ASCVD or High-Risk Conditions

• Order apoB in patients with established atherosclerotic cardiovascular disease to assess adequacy of lipid-lowering therapy, as it is superior to LDL-C for monitoring treatment response 3, 7
• Measure apoB in patients with chronic kidney disease stage 3 or 4, as these individuals have altered lipoprotein metabolism 4, 3

When ApoB Provides Superior Risk Assessment

Discordance Situations

• ApoB is the better predictor when discordant with non-HDL-C or LDL-C, affecting 8-23% of individuals 1
• When apoB and LDL-C are discordant, ASCVD risk aligns better with apoB levels 7, 8
• Even 2% discordance between apoB and LDL particle number shows elevated cardiovascular risk (HR 1.1 for both MACE and CAD), with risk increasing progressively to HR 2.5 for CAD at 30% discordance 8

Nonfasting Lipid Testing

• ApoB levels are not significantly changed in the postprandial state in individuals with triglycerides <4.5 mmol/L, making it ideal for nonfasting lipid assessment 1
• This contrasts with LDL-C, which can be lowered by up to 10% postprandially due to triglyceride enrichment 1

Practical Considerations

Guideline Recommendations

• The 2022 American Association of Clinical Endocrinology guidelines recommend apoB measurement as more accurate than non-HDL-C and superior to LDL-C for predicting ASCVD risk 4
• The 2021 Canadian Cardiovascular Society guidelines allow clinicians to use either non-HDL-C or apoB, but strongly urge routine use of either instead of LDL-C in all patients with triglycerides >1.5 mmol/L 1
• The 2017 AACE/ACE guidelines state apoB may be useful in at-risk individuals (TG ≥150 mg/dL, HDL-C <40 mg/dL, prior ASCVD, type 2 diabetes, insulin resistance) even at target LDL-C levels 3

Laboratory and Cost Issues

• ApoB testing incurs additional cost and analytical reliability may vary between laboratories 2
• ApoB is available as an insured laboratory test in all Canadian provinces except Ontario 1
• Despite cost concerns, apoB measurement is standardized, precise, and provides superior risk assessment compared to calculated LDL-C 9, 10, 11

Common Pitfalls to Avoid

• Do not rely solely on LDL-C when triglycerides are elevated, as calculated LDL-C systematically underestimates true LDL-C at values close to target levels 9
• Do not assume LDL-C and apoB provide equivalent information—they measure different aspects of atherogenic burden, with apoB directly counting particle number 7, 10
• Do not order apoB routinely in low-risk individuals without specific indications, as the cost-benefit ratio is less favorable 2
• Recognize that non-HDL-C is currently more practical than apoB in many settings because it incurs no additional expense, though apoB provides more accurate particle measurement 1